Final day to purchase Rakesh Jhunjhunwala-backed pharma stock to capture 1:1 bonus share issue

Market participants holding shares or purchasing them today become eligible for the 1:1 bonus share distribution announced by the Rakesh Jhunjhunwala-backed smallcap pharmaceutical company. Because of the Securities and Exchange Board of India (Sebi) T+1 settlement cycle, trades must execute at least one trading session before the designated record date to ensure shares reflect in demat accounts in time for entitlement. This procedural timeline establishes today as the absolute final opportunity for buyers to secure eligibility for the corporate action.

Corporate bonus issues expand a company's paid-up capital by issuing free additional shares to existing holders based on their current holding proportion, which traditionally improves market liquidity while adjusting per-share metrics. Under the standard settlement framework, ownership transfer happens swiftly on a T+1 basis, meaning transactions settled today meet the threshold for corporate action books. Investors tracking the pharmaceutical counter must complete their purchase orders before market close to participate in the corporate benefit.

Market participants and wealth advisors should verify trade execution timestamps and depository participant crediting schedules to ensure compliance with the corporate action cutoff. Portfolio managers and retail investors ought to factor in the subsequent price adjustment that typically accompanies a 1:1 bonus distribution. Bottom line: Verify your broker processes the trade before today's market close to secure your entitlement.